Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis is a research paper published in Radiology (2020). On theSindex it has a DataRank of 0. It has been cited 170 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Research Foundation of Korea
Grant: 2017R1A2B3011475
National Cancer Institute
Grant: R01CA203636
NCI NIH HHS
Grant: U01 CA209414
Fields of Study
MeSH Terms
Additional file 1 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 1 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 2 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 2 of Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
Additional file 1 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 1 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 2 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 2 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 3 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 3 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 4 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 4 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 5 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 5 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 6 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 7 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 6 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 7 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 8 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Additional file 8 of Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors